Plain-language summaries, not legal advice. Check the official source linked on each rule.
Possession
Up to 10 g not punished; use fined 100 francs
An adult who holds up to 10 g of cannabis for personal use is not punished, although the police can seize it. Consuming cannabis is still an offence: adults caught using it pay a fixed fine of 100 francs, or the case goes to a regular procedure. Minors are dealt with under juvenile law.
Penalties
Selling, growing or larger amounts: Narcotics Act penalties
Growing THC cannabis, selling it or holding more than a small amount for one's own use is an offence under Article 19 of the Narcotics Act, punishable by up to three years in prison or a fine; serious cases (large scale trafficking, gangs) carry at least one year. Using cannabis is a minor offence fined 100 francs for adults.
Retail Sale
CBD retail legal; THC retail only in pilot trials
CBD products below 1.0% THC are sold legally and widely available, regulated under food, cosmetics or tobacco-product law depending on the format. Adult-use THC cannabis may only be sold inside authorized scientific pilot trials (WeedCare in Basel-Stadt, ZüriCan in Zurich, SCRIPT and others) to registered participants resident in the trial canton. Commercial recreational retail outside these trials remains prohibited.
Homegrow
Home cultivation of THC cannabis prohibited
Cultivating cannabis with 1.0% THC or more is illegal in Switzerland, even a single plant for personal use, and can be prosecuted under the Narcotics Act. CBD hemp varieties below the threshold may be grown legally. In practice small-quantity cultivation is often handled with fines, but it is not decriminalized.
Medical
Doctors prescribe without a special permit since 2022
Since 1 August 2022 doctors can prescribe cannabis medicines with THC directly, without an exceptional permit from the FOPH. Health insurance pays only in some cases, so many patients pay themselves.
Driving
Zero tolerance for THC at the wheel
Switzerland applies zero tolerance: a THC concentration of 1.5 micrograms per litre of blood or more counts as unfit to drive, with a licence withdrawal and criminal charges. This also applies to legal CBD products if they push THC above the limit.
Advertising
Narcotics advertising banned
Advertising of narcotics, which includes all cannabis at or above 1.0% THC, is prohibited under the Narcotics Act. CBD products below the threshold may be marketed, but health or medical claims are not permitted and are policed under food and therapeutic-products law. Event sponsorship and lifestyle marketing for THC products are effectively banned.
THC Limits
1.0% THC threshold
The 1.0% total THC threshold determines whether a cannabis product falls under the Narcotics Act. Products below 1.0% are outside narcotics law but may be regulated as foodstuffs, cosmetics or tobacco substitutes depending on how they are sold. This threshold is stricter than the 0.2–0.3% common elsewhere in Europe, which is why Switzerland has a large legal CBD market.
Pilot Trials
Eight pilot trials sell cannabis legally to participants
Article 8a of the Narcotics Act allows scientific pilot trials with regulated sales to registered adult participants who already use cannabis. Eight trials were running by mid 2026, including Basel (Weed Care), Zurich (Züri Can), Bern, Biel and Lucerne (SCRIPT) and St. Gallen (CanLeg, approved in June 2026 and the first to test home delivery). Products are tested and sold through pharmacies, shops or social clubs depending on the trial.
Recent changes
The National Council's health committee adopted a draft law in February 2025 that would allow adults to buy cannabis from licensed, non profit outlets and grow three plants at home. After the consultation (August to December 2025), in which a majority of cantons were critical, the committee decided in May 2026 to continue the work but sent the text back to a subcommittee to revise youth protection, cantonal enforcement and online sales. No plenary debate is scheduled yet.
The FOPH approved the CanLeg trial in St. Gallen in June 2026, the eighth adult use pilot and the first to test delivery to participants' homes. Zurich extended its Züri Can trial to October 2028, and interim results from the SCRIPT trial in Bern, Biel and Lucerne (September 2026) showed no rise in consumption.